We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase.
- Authors
Park, Dahyun; Bea, Sungho; Bae, Ji-Hwan; Lee, Hyesung; Choe, Young June; Shin, Ju-Young; Kim, Hoon
- Abstract
Aims: Protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering agents used in patients with cardiovascular disease. Despite reassuring safety data from pivotal trials, increasing evidence from real-world studies suggests that PCSK9i increase the risk of bacterial and viral infections. Therefore, this study aimed to identify signals of infection-related adverse events (AEs) associated with PCSK9i. Methods: We performed an observational pharmacovigilance study using the World Health Organization's VigiBase, recorded up to December 2022. We included individual case safety reports (ICSRs) of PCSK9 inhibitors, alirocumab and evolocumab, and compared them with those of other drugs. Infection-related ICSRs were retrieved from the Medical Dictionary for Regulatory Activities System Organ Class 'infections and infestations.' Results: Among 114,293 reports (258,099 drug–AE pairs) related to PCSK9 inhibitors, 54% included female patients, 41% included patients aged ≥65 years, and 82% included patients who received evolocumab. Additionally, beyond AEs recognized by regulatory authorities, organ infections such as influenza (reporting odds ratio [ROR] 2.89, 95% confidence interval [CI] 2.74–3.05), gastric infections (ROR 2.47, 95% CI 1.63–3.75), and kidney infections (ROR 1.36, 95% CI 1.06–1.73) were observed. Sensitivity analysis indicated a heightened risk of infection-related AEs associated with PCSK9i regardless of the specific drug type. Conclusions: In addition to the labelled respiratory infections, six infection-related symptoms in the gastrointestinal, urinary, and renal organs were identified. Our findings support the need for systematic surveillance of infections among PCSK9i users.
- Subjects
ANTILIPEMIC agents; BACTERIAL diseases; RESPIRATORY infections; CARDIOVASCULAR diseases; ODDS ratio
- Publication
Drugs - Real World Outcomes, 2024, Vol 11, Issue 3, p465
- ISSN
2198-9788
- Publication type
Article
- DOI
10.1007/s40801-024-00430-5